Shatavari Root Extract for Perimenopausal Symptoms

Part of paid clinical trials in San Francisco, California.

Sponsor
SF Research Institute, Inc.
Study ID
NCT07441109
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
FEMALE
Age
40 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • Shatavari (Asparagus racemosus) Root Extract — DIETARY_SUPPLEMENT
    A standardized Shatavari root extract manufactured under cGMP conditions with an herb-to-extract ratio of 13:1 and standardized to contain ≥10% total Shatavarins. Participants will self-administer one capsule daily for 12 weeks.
  • Placebo Capsule — OTHER
    An inert starch-filled capsule identical in appearance, color, and packaging to the active intervention, administered once daily for 12 weeks to maintain blinding.

Study Details

This randomized, double-blind, placebo-controlled clinical study evaluates the efficacy and safety of a standardized Shatavari (Asparagus racemosus) root extract in women experiencing perimenopausal symptoms. Participants will receive either Shatavari root extract or a matched placebo for 12 weeks. Efficacy will be assessed using validated menopause-specific symptom, quality-of-life, stress, mood, and sleep questionnaires, along with physiological stress markers. Safety will be evaluated through laboratory assessments and adverse event monitoring.

Key Dates

Start date
Mar 11, 2026
Status verified
Feb 2026
Primary completion
Jun 15, 2026
Completion
Jun 29, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Shatavari Root Extract (SRI-81) 300 mg
    Participants will receive a standardized Shatavari (Asparagus racemosus) root extract capsule containing 300 mg, administered orally once daily after breakfast with water for 12 weeks.
  • Placebo Comparator: Placebo Capsule (Starch) 300 mg
    Participants will receive an identical placebo capsule containing 300 mg of starch, administered orally once daily after breakfast with water for 12 weeks.

Primary Outcome Measure

Change in Menopause Rating Scale (MRS) Total Score [ Time Frame: Baseline, Week 4, Week 8, Week 12 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
San Francisco Research InstituteSan FranciscoCalifornia94132
Komal Makwana
[email protected]
267-466-9000

Find similar trials in San Francisco, CA

By condition
Menopause
By specialty
Women's healthFertility
By research site
San Francisco Research Institute· San Francisco, CA

Related Studies